|
IP Group PLC - Oxford, England-based intellectual property commercialisation - Says portfolio company Autifony Therapeutics Ltd has signed a deal with Jazz Pharmaceuticals PLC worth up to $770 million for drug discovery and preclinical development on two ion channel targets associated with neurological disorders. Jazz will lead clinical development, manufacturing and regulatory activities and commercialisation once preclinical development is finalised. IP Group holds a 26% stake in Autifony, valued at £4.6 million. Current stock price: 46.55 pence, up 1.9% 12-month change: down 38% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
